Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
Carol Vidal Castro, MD - Reboxetine: An Alternative for Induced Bruxism
1
x
$
30.00
Depression Treatment: A Lifelong Commitment?
1
x
$
30.00
Understanding the Genotoxicity of Tamoxifen?
1
x
$
0.00
Test of Treatment in Psychiatric Practice by Feras Ali Mustafa
1
x
$
30.00
Letter From the Editors: Are We Prepared for the Genomics Era?
1
x
$
0.00
Induction of Psychosis by Cyclobenzaprine
1
x
$
30.00
Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia
1
x
$
30.00
An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis
1
x
$
30.00
ASD with the Bor Syndrome: A Case Report (OPEN ACCESS)
1
x
$
0.00
New Developments in Depression and Anxiety Disorders
1
x
$
30.00
The Important Role of Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphomas
1
x
$
0.00
Lori Davis, MD: Clinical and Pharmacoeconomic Evaluation of Switch to Olanzapine in Veterans with Schizophrenia or Schizoaffective Disorder
1
x
$
30.00
Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report
1
x
$
30.00
View Cart
Checkout
Home
Store
“Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report” has been added to your cart.
View cart
Sort by
Name
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
Divalproex in the Treatment of Migraine
$
30.00
Add to cart
Details
Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
$
30.00
Add to cart
Details
Does Isotretinoin Cause Depression and Suicide? By J. Douglas Bremner, MD
$
0.00
Add to cart
Details
Donald S. Robinson, MD: Monoamine Oxidase Inhibitors: A New Generation
$
30.00
Add to cart
Details
Donald S. Robinson, MD: Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder: A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials
$
30.00
Add to cart
Details
Dose-Dependent Urinary Incontinence with Sertraline Use in Obsessive-Compulsive Disorder
$
30.00
Add to cart
Details
Douglas G. Kondo, MD: An Evidence-Based Medicine Approach to Combined Treatment for ADHD in Children and Adolescents
$
30.00
Add to cart
Details
Dr. Juan E. Mezzich y Dr. Miguel R. Jorge: ¡Bienvenidos a Psiquiatría y Salud Integral!
$
0.00
Add to cart
Details
Drug Development for Anxiety Disorders: New Roles for Atypical Antipsychotics
$
30.00
Add to cart
Details
Drug Induced Mania in a Boy with High Functioning Autism
$
30.00
Add to cart
Details
Drug–Drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients
$
30.00
Add to cart
Details
Duloxetine for the Treatment of Major Depressive Disorder
$
30.00
Add to cart
Details
Duloxetine in Military Posttraumatic Stress Disorder
$
30.00
Add to cart
Details
Duration of Untreated Illness in Obsessive-Compulsive Disorder and its Associated Factors
$
30.00
Add to cart
Details
E. Chris Muly, MD, PhD: Signal Transduction Abnormalities in Schizophrenia: the cAMP System
$
30.00
Add to cart
Details
Early Positive Report of Viloxazine for a Child with Hyperkinetic Autism
$
30.00
Add to cart
Details
Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders
$
30.00
Add to cart
Details
Economic Impacts of Anxiety Disorders
$
0.00
Add to cart
Details
Economics of Cancer Drug Development
$
0.00
Add to cart
Details
EDITOR’S LETTER: Charles B. Nemeroff, MD, PhD
$
0.00
Add to cart
Details
Previous
1
…
11
12
13
…
44
Next
Page load link
Go to Top
